Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bone marrow failure01.03.03.0050.001007%
Nephritic syndrome20.05.01.0060.000112%Not Available
Bronchial haemorrhage24.07.01.045; 22.03.02.007--Not Available
Treatment failure08.06.01.017--Not Available
Liver injury12.01.17.012; 09.01.07.0220.000504%Not Available
Regurgitation07.01.07.0040.000246%Not Available
Oral disorder07.05.01.0050.000381%Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.0020.004667%Not Available
Hypertransaminasaemia09.01.02.0050.000392%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Gastrointestinal tract irritation07.08.03.0080.000381%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.001063%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000783%Not Available
Autoimmune haemolytic anaemia10.04.01.005; 01.06.01.0040.000168%Not Available
Faeces soft07.01.03.0080.000437%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.001343%
Anal incontinence07.01.06.029; 17.05.01.0210.000571%
Frustration tolerance decreased19.04.02.0160.000246%Not Available
Ureterolithiasis20.04.03.0030.000112%Not Available
Angiosarcoma24.03.06.003; 16.16.03.0010.000560%Not Available
Bone cancer16.29.02.002; 15.09.03.0120.000168%Not Available
Brain neoplasm malignant17.20.04.002; 16.30.04.0020.000302%Not Available
Concomitant disease aggravated08.01.03.0630.000750%Not Available
Dermatitis exfoliative generalised23.03.07.002; 10.01.01.0290.000224%Not Available
Ewing's sarcoma16.29.03.004; 15.09.03.0150.000112%Not Available
Faeces pale07.01.03.0050.000548%Not Available
Leiomyosarcoma15.09.03.016; 16.33.07.0010.000168%Not Available
Leiomyosarcoma metastatic16.33.07.002; 15.09.03.0170.000112%Not Available
Liposarcoma15.09.03.005; 16.33.05.0010.000112%Not Available
Malignant pleural effusion22.05.04.001; 16.32.03.0140.000224%Not Available
The 18th Page    First    Pre   18 19 20 21    Next   Last    Total 21 Pages